Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naltrexone POA Pharma
- Development stage
- Unknown
- Lead developer
- POA Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Naltrexone POA Pharma is a generic formulation of naltrexone hydrochloride, a potent and long-acting opioid antagonist. Commercialized by Galen (a member of the Almac Group) following its acquisition of POA Pharma, the drug is used as an adjunct in the treatment of alcohol and opioid dependence. It functions by competitively binding to opioid receptors in the central nervous system, effectively blocking the euphoric effects of exogenous opioids and reducing the craving for alcohol. The product is typically administered orally as a 50 mg film-coated tablet and is intended for use in patients who have already undergone detoxification and are committed to maintaining abstinence.
- Brand names
- Naltrexone POA Pharma
- Other names
- naltrexone hydrochloridenaltrexone-Galen
02
Targets
KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)
Beyond the preview
Go deeper on Naltrexone POA Pharma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Naltrexone POA Pharma.